Bevazza 100mg Injection is a targeted therapy used in the treatment of certain types of cancer. Its active ingredient, bevacizumab, is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). By blocking VEGF, Bevazza prevents the formation of new blood vessels that tumors need to grow and spread. This mechanism of action, known as anti-angiogenesis, helps to slow down or stop tumor progression.
Bevazza is indicated for the treatment of metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, and metastatic renal cell carcinoma, often in combination with chemotherapy. The dosage and administration of Bevazza should be determined by a qualified healthcare professional based on the specific cancer type, stage, and individual patient factors. It is administered intravenously.
Common side effects may include hypertension, proteinuria, fatigue, and nosebleeds. More serious side effects can occur and require immediate medical attention. Patients should discuss potential risks and benefits with their doctor. Bevazza should be stored at refrigerator temperatures (2°C to 8°C) and protected from light. Do not freeze.
